John P H Wilding

List of Publications by Citations

320 papers	25,197 citations	68 h-index	155 g-index
360 ext. papers	30,726 ext. citations	7.8 avg, IF	7.22 L-index

#	Paper	IF	Citations
320	Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*, **2019**, 380, 347-357	59.2	2455
319	Alogliptin after acute coronary syndrome in patients with type 2 diabetes. *New England Journal of Medicine*, **2013**, 369, 1327-35	59.2	1858
318	A role for glucagon-like peptide-1 in the central regulation of feeding. *Nature*, **1996**, 379, 69-72	50.4	1520
317	SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. *Lancet, The* , **2019**, 393, 31-39	40	1300
316	A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. *New England Journal of Medicine*, **2015**, 373, 11-22	59.2	950
315	Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. *Lancet, The*, **2015**, 385, 2067-76	40	551
314	Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, 1020-31	5.6	548
313	Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. *European Heart Journal*, **2004**, 25, 735-41	9.5	539
312	Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). *Circulation*, **2017**, 136, 249-259	16.7	519
311	Management of obesity. *Lancet, The*, **2016**, 387, 1947-56	40	461
310	Once-Weekly Semaglutide in Adults with Overweight or Obesity. *New England Journal of Medicine*, **2021**, 384, 989	59.2	351
309	Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. *Circulation*, **2019**, 139, 2022-2031	16.7	345
308	Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. *Annals of Internal Medicine*, **2012**, 156, 405-15	8	340
307	Food fails to suppress ghrelin levels in obese humans. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 2984	5.6	340
306	3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. *Lancet, The*, **2017**, 389, 1399-1409	40	324
305	Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. *Diabetes, Obesity and Metabolism*, **2014**, 16, 159-69	6.7	321
304	A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. *Diabetes Care*, **2009**, 32, 1656-62	14.6	312

303	Anti-obesity drugs: past, present and future. *DMM Disease Models and Mechanisms*, **2012**, 5, 621-6	4.1	306
302	Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. *Lancet Diabetes and Endocrinology,the*, **2019**, 7, 606-617	18.1	304
301	Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. *Diabetes*, **2017**, 66, 241-255	25	292
300	Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. *Circulation*, **2019**, 139, 2528-2536	16.7	283
299	Hypothalamic orexin expression: modulation by blood glucose and feeding. *Diabetes*, **1999**, 48, 2132-7	0.9	266
298	Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study. *Journal of the American College of Cardiology*, **2018**, 71, 2628-2639	15.1	263
297	Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. *Archives of Internal Medicine*, **2000**, 160, 1321-6		250
296	Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. *International Journal of Clinical Practice*, **2013**, 67, 1267-82	2.9	245
295	Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. *Lancet, The*, **2018**, 392, 637-649	40	242
294	Cardiovascular and metabolic effects of CPAP in obese males with OSA. *European Respiratory Journal*, **2007**, 29, 720-7	13.6	237
293	Sleep-disordered breathing and type 2 diabetes: a report from the International Diabetes Federation Taskforce on Epidemiology and Prevention. *Diabetes Research and Clinical Practice*, **2008**, 81, 2-12	7.4	224
292	Vitamin D signalling in adipose tissue. *British Journal of Nutrition*, **2012**, 108, 1915-23	3.6	210
291	Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. *Diabetes, Obesity and Metabolism*, **2014**, 16, 124-36	6.7	198
290	Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 34-42	5.6	195
289	Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. *Postgraduate Medical Journal*, **2006**, 82, 280-4	2	185
288	Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. *Lancet Diabetes and Endocrinology,the*, **2017**, 5, 597-609	18.1	177
287	A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. *Journal of the American College of Cardiology*, **2007**, 49, 1696-704	15.1	170
286	A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. *International Journal of Obesity*, **2004**, 28, 1399-410	5.5	166

285	Gut peptides and the regulation of appetite. *Obesity Reviews*, **2006**, 7, 163-82	10.6	162
284	Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. *Diabetes, Obesity and Metabolism*, **2012**, 14, 990-9	6.7	154
283	Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. *Circulation*, **2019**, 139, 2516-2527	16.7	142
282	Identification of macrophage inhibitory cytokine-1 in adipose tissue and its secretion as an adipokine by human adipocytes. *Endocrinology*, **2009**, 150, 1688-96	4.8	137
281	Dietary advice based on the glycaemic index improves dietary profile and metabolic control in type 2 diabetic patients. *Diabetic Medicine*, **1994**, 11, 397-401	3.5	135
280	The importance of weight management in type 2 diabetes mellitus. *International Journal of Clinical Practice*, **2014**, 68, 682-91	2.9	133
279	The importance of free fatty acids in the development of Type 2 diabetes. *Diabetic Medicine*, **2007**, 24, 934-45	3.5	133
278	Neuropeptides and appetite control. *Diabetic Medicine*, **2002**, 19, 619-27	3.5	125
277	Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution. *British Journal of Pharmacology*, **1999**, 128, 1570-6	8.6	117
276	The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. *Metabolism: Clinical and Experimental*, **2014**, 63, 1228-37	12.7	115
275	Identification, assessment, and management of overweight and obesity: summary of updated NICE guidance. *BMJ, The*, **2014**, 349, g6608	5.9	115
274	Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. *Lancet Diabetes and Endocrinology,the*, **2020**, 8, 27-35	18.1	109
273	A parametric analysis of olanzapine-induced weight gain in female rats. *Psychopharmacology*, **2005**, 181, 80-9	4.7	103
272	Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. *Diabetes, Obesity and Metabolism*, **2013**, 15, 403-9	6.7	98
271	SPARC: a key player in the pathologies associated with obesity and diabetes. *Nature Reviews Endocrinology*, **2010**, 6, 225-35	15.2	98
270	Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial. *Circulation*, **2020**, 141, 1227-1234	16.7	97
269	Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial. *Diabetes, Obesity and Metabolism*, **2005**, 7, 755-61	6.7	97
268	An audit of 500 subcutaneous glucagon stimulation tests to assess growth hormone and ACTH secretion in patients with hypothalamic-pituitary disease. *Clinical Endocrinology*, **2001**, 54, 463-8	3.4	95

267	Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus. *European Journal of Clinical Investigation*, **1997**, 27, 533-6	4.6	90
266	Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. *Diabetologia*, **2015**, 58, 1183-7	10.3	89
265	The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. *American Heart Journal*, **2018**, 200, 83-89	4.9	89
264	Regulation of the fibrosis and angiogenesis promoter SPARC/osteonectin in human adipose tissue by weight change, leptin, insulin, and glucose. *Diabetes*, **2009**, 58, 1780-8	0.9	86
263	Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities. *Journal of Psychopharmacology*, **2007**, 21, 405-13	4.6	86
262	The adipokine zinc-alpha2-glycoprotein (ZAG) is downregulated with fat mass expansion in obesity. *Clinical Endocrinology*, **2010**, 72, 334-41	3.4	84
261	DECLARE-TIMI 58: Participants□baseline characteristics. *Diabetes, Obesity and Metabolism*, **2018**, 20, 1102-1110	3.7	80
260	Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1). *Journal of the Endocrine Society*, **2021**, 5, A10-A10	0.4	78
259	Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. *Obesity*, **2020**, 28, 1050-1061	8	77
258	Increased neuropeptide Y content in individual hypothalamic nuclei, but not neuropeptide Y mRNA, in diet-induced obesity in rats. *Journal of Endocrinology*, **1992**, 132, 299-304	4.7	73
257	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. *American Heart Journal*, **2015**, 169, 631-638.e7	4.9	72
256	What have human experimental overfeeding studies taught us about adipose tissue expansion and susceptibility to obesity and metabolic complications?. *International Journal of Obesity*, **2017**, 41, 853-865	5.5	68
255	Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. *Journal of Diabetes and Its Complications*, **2013**, 27, 268-73	3.2	68
254	SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL. *Journal of the American College of Cardiology*, **2018**, 71, 2497-2506	15.1	68
253	1,25-dihydroxyvitamin D3 protects against macrophage-induced activation of NFB and MAPK signalling and chemokine release in human adipocytes. *PLoS ONE*, **2013**, 8, e61707	3.7	65
252	Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. *Diabetic Medicine*, **2004**, 21, 415-22	3.5	65
251	Down-regulation of orexin gene expression by severe obesity in the rats: studies in Zucker fatty and zucker diabetic fatty rats and effects of rosiglitazone. *Molecular Brain Research*, **2000**, 77, 131-7		63
250	The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats. *British Journal of Pharmacology*, **2005**, 144, 308-16	8.6	62

249	Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. *International Journal of Clinical Practice*, **2002**, 56, 494-9	2.9	62
248	Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers. *Obesity*, **2016**, 24, 2278-2288	8	60
247	Increases in neuropeptide Y content and gene expression in the hypothalamus of rats treated with dexamethasone are prevented by insulin. *Neuroendocrinology*, **1993**, 57, 581-7	5.6	60
246	Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin. *Diabetes, Obesity and Metabolism*, **2013**, 15, 750-9	6.7	59
245	Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. *Circulation*, **2019**, 140, 1569-1577	16.7	57
244	Hypothalamic obesity in humans: what do we know and what can be done?. *Obesity Reviews*, **2002**, 3, 27-34	10.6	56
243	Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study. *Diabetes, Obesity and Metabolism*, **2018**, 20, 1983-1987	6.7	55
242	Plasma obestatin levels are lower in obese and post-gastrectomy subjects, but do not change in response to a meal. *International Journal of Obesity*, **2008**, 32, 129-35	5.5	55
241	Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities. *Obesity Reviews*, **2019**, 20, 816-828	10.6	54
240	Short-term decreased physical activity with increased sedentary behaviour causes metabolic derangements and altered body composition: effects in individuals with and without a first-degree relative with type 2 diabetes. *Diabetologia*, **2018**, 61, 1282-1294	10.3	54
239	Plasma adiponectin increases postprandially in obese, but not in lean, subjects. *Obesity*, **2003**, 11, 839-44		54
238	Thiazolidinediones, insulin resistance and obesity: Finding a balance. *International Journal of Clinical Practice*, **2006**, 60, 1272-80	2.9	52
237	Insulin resistance and inflammatory activation in older patients with systolic and diastolic heart failure. *Heart*, **2005**, 91, 32-7	5.1	51
236	Abdominal obesity, impaired nonesterified fatty acid suppression, and insulin-mediated glucose disposal are early metabolic abnormalities in families with premature myocardial infarction. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1998**, 18, 1021-6	9.4	51
235	PPAR agonists for the treatment of cardiovascular disease in patients with diabetes. *Diabetes, Obesity and Metabolism*, **2012**, 14, 973-82	6.7	50
234	Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition. *Diabetes, Obesity and Metabolism*, **2016**, 18, 125-34	6.7	50
233	E-cadherin transfection down-regulates the epidermal growth factor receptor and reverses the invasive phenotype of human papilloma virus-transfected keratinocytes. *Cancer Research*, **1996**, 56, 5285-92	10.1	49
232	Science, medicine, and the future. Obesity treatment. *BMJ: British Medical Journal*, **1997**, 315, 997-1000		48

231	Night eating syndrome: implications for severe obesity. *Nutrition and Diabetes*, **2012**, 2, e44	4.7	45
230	Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. *Diabetes, Obesity and Metabolism*, **2018**, 20, 2210-2219	6.7	44
229	A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors. *Diabetes, Obesity and Metabolism*, **2019**, 21 Suppl 2, 9-18	6.7	43
228	Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes. *Clinical Endocrinology*, **2009**, 71, 195-201	3.4	43
227	Obesity and diabetes. *Best Practice and Research in Clinical Endocrinology and Metabolism*, **1999**, 13, 221-37	8.5	41
226	Lack of acute effect of amylin (islet associated polypeptide) on insulin sensitivity during hyperinsulinaemic euglycaemic clamp in humans. *Diabetologia*, **1994**, 37, 166-9	10.3	41
225	Diet-induced endothelial dysfunction in the rat is independent of the degree of increase in total body weight. *Clinical Science*, **2001**, 100, 635-41	6.5	40
224	Exposure-response analyses of liraglutide 3.0 mg for weight management. *Diabetes, Obesity and Metabolism*, **2016**, 18, 491-9	6.7	40
223	SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice. *Diabetes Therapy*, **2018**, 9, 1757-1773	3.6	39
222	Additive effects of lactation and food restriction to increase hypothalamic neuropeptide Y mRNA in rats. *Journal of Endocrinology*, **1997**, 152, 365-9	4.7	39
221	Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus. *Journal of Diabetes and Its Complications*, **2015**, 29, 438-44	3.2	38
220	Risk of misdiagnosis, health-related quality of life, and BMI in patients who are overweight with doctor-diagnosed asthma. *Chest*, **2012**, 141, 616-624	5.3	38
219	Dietary obesity in the rat induces endothelial dysfunction without causing insulin resistance: a possible role for triacylglycerols. *Clinical Science*, **2001**, 101, 499-506	6.5	38
218	Sleep disordered breathing--a new component of syndrome x?. *Obesity Reviews*, **2001**, 2, 267-74	10.6	38
217	Effect of a cooked meat meal on serum creatinine and estimated glomerular filtration rate in diabetes-related kidney disease. *Diabetes Care*, **2014**, 37, 483-7	14.6	37
216	Impact of bariatric surgery on physical functioning in obese adults. *Obesity Reviews*, **2015**, 16, 248-58	10.6	36
215	Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus. *Diabetic Medicine*, **2012**, 29, e205-10	3.5	36
214	The four-variable modification of diet in renal disease formula underestimates glomerular filtration rate in obese type 2 diabetic individuals with chronic kidney disease. *Diabetologia*, **2011**, 54, 1304-7	10.3	36

213	SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. *Lancet, The*, **2021**, 398, 262-276	40	35
212	Cardiac Autonomic Neuropathy in Obesity, the Metabolic Syndrome and Prediabetes: A Narrative Review. *Diabetes Therapy*, **2019**, 10, 1995-2021	3.6	34
211	Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response. *American Journal of Physiology - Endocrinology and Metabolism*, **2017**, 312, E224-E233	6	33
210	Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes. *Diabetes and Vascular Disease Research*, **2007**, 4, 194-203	3.3	33
209	Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study. *Diabetes Care*, **2020**, 43, 468-475	14.6	33
208	Sleep-disordered breathing, type 2 diabetes and the metabolic syndrome. *Chronic Respiratory Disease*, **2014**, 11, 257-75	3	32
207	Effect of food deprivation and streptozotocin-induced diabetes on hypothalamic neuropeptide Y release as measured by a radioimmunoassay-linked microdialysis procedure. *Brain Research*, **1994**, 656, 135-40	3.7	32
206	The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women. *Journal of Psychopharmacology*, **2010**, 24, 99-109	4.6	30
205	Time for a new obesity narrative. *Lancet, The*, **2018**, 392, 1384-1386	40	30
204	Newer GLP-1 receptor agonists and obesity-diabetes. *Peptides*, **2018**, 100, 61-67	3.8	29
203	Human RBP4 adipose tissue expression is gender specific and influenced by leptin. *Clinical Endocrinology*, **2011**, 74, 197-205	3.4	29
202	The effect of continuous positive airway pressure usage on sleepiness in obstructive sleep apnoea: real effects or expectation of benefit?. *Thorax*, **2012**, 67, 920-4	7.3	29
201	Absence of insulin signalling in skeletal muscle is associated with reduced muscle mass and function: evidence for decreased protein synthesis and not increased degradation. *Age*, **2010**, 32, 209-22		29
200	The relationship of ghrelin to biochemical and anthropometric markers of adult growth hormone deficiency. *Clinical Endocrinology*, **2004**, 60, 137-41	3.4	29
199	Adipokines and the insulin resistance syndrome in familial partial lipodystrophy caused by a mutation in lamin A/C. *Diabetologia*, **2005**, 48, 2641-9	10.3	29
198	Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm. *Diabetes Care*, **2016**, 39 Suppl 2, S154-64	14.6	28
197	Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink. *BMC Medicine*, **2018**, 16, 116	11.4	28
196	Metformin prolongs the postprandial fall in plasma ghrelin concentrations in type 2 diabetes. *Diabetes/Metabolism Research and Reviews*, **2007**, 23, 299-303	7.5	28

195	Clinical presentation of thyroid dysfunction and Addison's disease in young adults with type 1 diabetes. *Postgraduate Medical Journal*, **1999**, 75, 467-70	2	28
194	Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. *Diabetes, Obesity and Metabolism*, **2017**, 19, 1529-1536	6.7	27
193	Ghrelin restores 'lean-type' hunger and energy expenditure profiles in morbidly obese subjects but has no effect on postgastrectomy subjects. *International Journal of Obesity*, **2009**, 33, 317-25	5.5	27
192	Assessment of quality of life in adults receiving long-term growth hormone replacement compared to control subjects. *Clinical Endocrinology*, **2003**, 59, 75-81	3.4	27
191	Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wistar rats independently of hypothalamic neuropeptide Y. *British Journal of Pharmacology*, **2001**, 132, 1898-904	8.6	27
190	Lack of an acute effect of ghrelin on markers of bone turnover in healthy controls and post-gastrectomy subjects. *Bone*, **2007**, 41, 406-13	4.7	26
189	Successful cardiovascular risk reduction in Type 2 diabetes by nurse-led care using an open clinical algorithm. *Diabetic Medicine*, **2006**, 23, 780-7	3.5	26
188	Leptin and the control of obesity. *Current Opinion in Pharmacology*, **2001**, 1, 656-61	5.1	26
187	Medication use for the treatment of diabetes in obese individuals. *Diabetologia*, **2018**, 61, 265-272	10.3	25
186	SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into Practice. *Diabetes Therapy*, **2019**, 10, 1595-1622	3.6	24
185	Acute peripheral administration of synthetic human GLP-1 (7-36 amide) decreases circulating IL-6 in obese patients with type 2 diabetes mellitus: a potential role for GLP-1 in modulation of the diabetic pro-inflammatory state?. *Regulatory Peptides*, **2013**, 183, 54-61		23
184	Obstructive sleep apnea is associated with increased arterial stiffness in severe obesity. *Journal of Sleep Research*, **2014**, 23, 700-708	5.8	22
183	Obstructive sleep apnoea in patients with type 2 diabetes: aetiology and implications for clinical care. *Diabetes, Obesity and Metabolism*, **2009**, 11, 733-41	6.7	22
182	Effects of insulin-induced hypoglycaemia on energy intake and food choice at a subsequent test meal. *Diabetes/Metabolism Research and Reviews*, **2004**, 20, 405-10	7.5	22
181	Is there a role for ghrelin and peptide-YY in the pathogenesis of obesity in adults with acquired structural hypothalamic damage?. *Journal of Clinical Endocrinology and Metabolism*, **2005**, 90, 5025-30	5.6	22
180	Ghrelin inhibits autonomic function in healthy controls, but has no effect on obese and vagotomized subjects. *Clinical Endocrinology*, **2010**, 73, 678-85	3.4	21
179	Treatment strategies for obesity. *Obesity Reviews*, **2007**, 8 Suppl 1, 137-44	10.6	21
178	Obesity in the global haemophilia population: prevalence, implications and expert opinions for weight management. *Obesity Reviews*, **2018**, 19, 1569-1584	10.6	21

177	Combination therapy for obesity. *Journal of Psychopharmacology*, **2017**, 31, 1503-1508	4.6	20
176	A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus. *Clinical Endocrinology*, **2012**, 77, 635-7	3.4	20
175	Neurobiology. *British Medical Bulletin*, **1997**, 53, 286-306	5.4	20
174	Intensified treatment of type 2 diabetes--positive effects on blood pressure, but not glycaemic control. *QJM - Monthly Journal of the Association of Physicians*, **2003**, 96, 833-6	2.7	20
173	Abnormal heart rate variability in adults with growth hormone deficiency. *Journal of Clinical Endocrinology and Metabolism*, **2000**, 85, 628-33	5.6	20
172	GLP-1 as a target for therapeutic intervention. *Current Opinion in Pharmacology*, **2016**, 31, 44-49	5.1	20
171	Physical Activity and Sedentary Time: Association with Metabolic Health and Liver Fat. *Medicine and Science in Sports and Exercise*, **2019**, 51, 1169-1177	1.2	20
170	Reduced ventromedial hypothalamic neuronal nitric oxide synthase and increased sensitivity to NOS inhibition in dietary obese rats: further evidence of a role for nitric oxide in the regulation of energy balance. *Brain Research*, **2004**, 1016, 222-8	3.7	19
169	Dietary obesity in the rat induces endothelial dysfunction without causing insulin resistance: a possible role for triacylglycerols. *Clinical Science*, **2001**, 101, 499	6.5	19
168	Insulin-sensitizing action of rosiglitazone is enhanced by preventing hyperphagia. *Diabetes, Obesity and Metabolism*, **2001**, 3, 171-80	6.7	19
167	Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. *Hypertension*, **2016**, 68, 606-13	8.5	18
166	Cardiovascular disease, hypertension, dyslipidaemia and obesity in patients with hypothalamic-pituitary disease. *Postgraduate Medical Journal*, **2007**, 83, 277-80	2	18
165	Diet-induced endothelial dysfunction in the rat is independent of the degree of increase in total body weight. *Clinical Science*, **2001**, 100, 635	6.5	18
164	Glycated Hemoglobin, Body Weight and Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Primary Care: A Retrospective Study. *Diabetes Therapy*, **2016**, 7, 695-711	3.6	18
163	Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes (SCORE-IT): a patient and healthcare professional consensus on a core outcome set for type 2 diabetes. *BMJ Open Diabetes Research and Care*, **2019**, 7, e000700	4.5	18
162	Are the causes of obesity primarily environmental? Yes. *BMJ, The*, **2012**, 345, e5843	5.9	17
161	Effects of S 15511, a therapeutic metabolite of the insulin-sensitizing agent S 15261, in the Zucker Diabetic Fatty rat. *Diabetes, Obesity and Metabolism*, **2007**, 9, 114-20	6.7	17
160	Screening for obstructive sleep apnoea in obesity and diabetes--potential for future approaches. *European Journal of Clinical Investigation*, **2013**, 43, 640-55	4.6	16

159	Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58. *European Journal of Heart Failure*, **2021**, 23, 1026-1036	12.3	16
158	Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. *Circulation*, **2020**, 142, 734-747	16.7	16
157	Incorporating patientsQperspectives into the initial stages of core outcome set development: a rapid review of qualitative studies of type 2 diabetes. *BMJ Open Diabetes Research and Care*, **2019**, 7, e000615	4.5	15
156	Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes. *Diabetes, Obesity and Metabolism*, **2020**, 22, 1094-1101	6.7	15
155	Glucagon-like peptide-1 analogues for type 2 diabetes. *BMJ, The*, **2011**, 342, d410	5.9	15
154	Fasting plasma peptide-YY concentrations are elevated but do not rise postprandially in type 2 diabetes. *Diabetologia*, **2006**, 49, 2219-21	10.3	15
153	The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD). *Peptides*, **2020**, 125, 170208	3.8	15
152	Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus. *International Journal of Clinical Practice*, **2017**, 71, e12948	2.9	14
151	Liraglutide in the treatment of obesity. *Expert Opinion on Biological Therapy*, **2014**, 14, 1215-24	5.4	14
150	Urinary proteomics in obstructive sleep apnoea and obesity. *European Journal of Clinical Investigation*, **2014**, 44, 1104-15	4.6	14
149	Hypothalamic obesity: prevalence, associations and longitudinal trends in weight in a specialist adult neuroendocrine clinic. *European Journal of Endocrinology*, **2013**, 168, 501-7	6.5	14
148	Improved glycaemic control--an unintended benefit of a nurse-led cardiovascular risk reduction clinic. *Diabetic Medicine*, **2005**, 22, 1272-4	3.5	14
147	Obesity: under-diagnosed and under-treated in hospital outpatient departments. *International Journal of Obesity*, **2002**, 26, 581-4	5.5	14
146	Economic impacts of overweight and obesity: current and future estimates for eight countries. *BMJ Global Health*, **2021**, 6,	6.6	14
145	A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus. *Diabetes Research and Clinical Practice*, **2018**, 146, 240-250	7.4	14
144	Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial. *Diabetes, Obesity and Metabolism*, **2020**, 22, 1122-1131	6.7	13
143	Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study. *Diabetes, Obesity and Metabolism*, **2020**, 22, 1357-1368	6.7	13
142	Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up. *Primary Care Diabetes*, **2017**, 11, 437-444	2.4	13

141	Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. *International Journal of Clinical Practice*, **2015**, 69, 186-98	2.9	13
140	Chronic treatment with the thiazolidinedione, MCC-555, is associated with reductions in nitric oxide synthase activity and beta-cell apoptosis in the pancreas of the Zucker Diabetic Fatty rat. *International Journal of Experimental Pathology*, **2003**, 84, 83-9	2.8	13
139	Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: a randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)-study protocol. *BMJ Open*, **2017**, 7, e013539	3	12
138	Arrhythmogenic gene remodelling in elderly patients with type 2 diabetes with aortic stenosis and normal left ventricular ejection fraction. *Experimental Physiology*, **2017**, 102, 1424-1434	2.4	12
137	How to approach endocrine assessment in severe obesity?. *Clinical Endocrinology*, **2013**, 79, 163-7	3.4	12
136	Cardiovascular outcome trials in obesity: A review. *Obesity Reviews*, **2021**, 22, e13112	10.6	12
135	Vitamin D receptor ligands attenuate the inflammatory profile of IL-1Β stimulated human white preadipocytes via modulating the NF-Β and unfolded protein response pathways. *Biochemical and Biophysical Research Communications*, **2018**, 503, 1049-1056	3.4	12
134	Effect of CPAP on arterial stiffness in severely obese patients with obstructive sleep apnoea. *Sleep and Breathing*, **2015**, 19, 1155-65	3.1	11
133	Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events. *BMJ Open Diabetes Research and Care*, **2020**, 8,	4.5	11
132	Ghrelin does not orchestrate the metabolic changes seen in fasting but has significant effects on lipid mobilisation and substrate utilisation. *European Journal of Endocrinology*, **2011**, 165, 45-55	6.5	11
131	Clinical evaluation of anti-obesity drugs. *Current Drug Targets*, **2004**, 5, 325-32	3	11
130	Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real-world evidence. *Diabetes, Obesity and Metabolism*, **2020**, 22, 2364-2374	6.7	11
129	Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58. *Diabetes, Obesity and Metabolism*, **2021**, 23, 29-38	6.7	11
128	SCORE-IT (Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes): a systematic review of registered trials. *Trials*, **2017**, 18, 597	2.8	10
127	Should obesity be recognised as a disease?. *BMJ, The*, **2019**, 366, l4258	5.9	10
126	Characteristics and perspectives of night-eating behaviour in a severely obese population. *Clinical Obesity*, **2014**, 4, 30-8	3.6	10
125	The influence of growth hormone replacement on heart rate variability in adults with growth hormone deficiency. *Clinical Endocrinology*, **2001**, 54, 819-26	3.4	10
124	Reduced NPY induced feeding in diabetic but not steroid-treated rats: lack of evidence for changes in receptor number or affinity. *Journal of Neuroendocrinology*, **1996**, 8, 283-90	3.8	10

123	The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection. *Annals of Medicine*, **2021**, 53, 2072-2089	1.5	10
122	The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. *Diabetes Care*, **2021**, 44, 1805-1815	14.6	10
121	Altered Left Ventricular Ion Channel Transcriptome in a High-Fat-Fed Rat Model of Obesity: Insight into Obesity-Induced Arrhythmogenesis. *Journal of Obesity*, **2016**, 2016, 7127898	3.7	10
120	SGLT2 inhibitors and urinary tract infections. *Nature Reviews Endocrinology*, **2019**, 15, 687-688	15.2	10
119	Fit for Birth - the effect of weight changes in obese pregnant women on maternal and neonatal outcomes: a pilot prospective cohort study. *Clinical Obesity*, **2016**, 6, 79-88	3.6	9
118	PatientsQPerspectives of Oral and Injectable Type 2 Diabetes Medicines, Their Body Weight and Medicine-Taking Behavior in the UK: A Systematic Review and Meta-Ethnography. *Diabetes Therapy*, **2018**, 9, 1791-1810	3.6	9
117	Plasma obestatin and autonomic function are altered in orexin-deficient narcolepsy, but ghrelin is unchanged. *Endocrine*, **2013**, 43, 696-704	4	9
116	Evaluation of Aintree LOSS, a community-based, multidisciplinary weight management service: outcomes and predictors of engagement. *Clinical Obesity*, **2017**, 7, 368-376	3.6	9
115	Serum urate and obstructive sleep apnoea in severe obesity. *Chronic Respiratory Disease*, **2015**, 12, 238-46	3	9
114	From history to reality: sodium glucose co-transporter 2 inhibitors a novel therapy for type 2 diabetes mellitus. *Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide*, **2010**, 27, 311-316		9
113	Differential vascular dysfunction in response to diets of differing macronutrient composition: a phenomenonological study. *Nutrition and Metabolism*, **2007**, 4, 15	4.6	9
112	SGLT2 inhibition and ketoacidosis should we be concerned?. *British Journal of Diabetes and Vascular Disease*, **2015**, 15, 155		9
111	244-OR: Effects of Dapagliflozin on the Urinary Albumin-to-Creatinine Ratio in Patients with Type 2 Diabetes: A Predefined Analysis from the DECLARE-TIMI 58 Randomised, Placebo-Controlled Trial. *Diabetes*, **2019**, 68, 244-OR	0.9	9
110	Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data. *International Journal of Obesity*, **2021**, 45, 923-933	5.5	9
109	Pathophysiology and aetiology of obesity. *Medicine*, **2015**, 43, 73-76	0.6	8
108	A safety evaluation of canagliflozin : a first-in-class treatment for type 2 diabetes. *Expert Opinion on Drug Safety*, **2014**, 13, 1535-44	4.1	8
107	Obesity and type-2 diabetes in the elderly. *Gerontology*, **2003**, 49, 137-45	5.5	8
106	Troglitazone corrects metabolic changes but not vascular dysfunction in dietary-obese rats. *European Journal of Pharmacology*, **2001**, 416, 133-9	5.3	8

105	The prevalence of cardiac autonomic neuropathy in prediabetes: a systematic review. *Diabetologia*, **2021**, 64, 288-303	10.3	8
104	The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial. *Diabetes, Obesity and Metabolism*, **2021**, 23, 1020-1029	6.7	8
103	Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10. *Diabetes Care*, **2018**, 41, e106-e108	14.6	8
102	Correlations between night eating, sleep quality, and excessive daytime sleepiness in a severely obese UK population. *Sleep Medicine*, **2013**, 14, 1151-6	4.6	7
101	Nurse-led clinics for strict hypertension control are effective long term: a 7 year follow-up study. *Diabetic Medicine*, **2010**, 27, 933-7	3.5	7
100	Energy restriction enhances therapeutic efficacy of the PPARgamma agonist, rosiglitazone, through regulation of visceral fat gene expression. *Diabetes, Obesity and Metabolism*, **2008**, 10, 251-63	6.7	7
99	Pathophysiology and aetiology of obesity. *Medicine*, **2006**, 34, 501-505	0.6	7
98	Acute effects of central neuropeptide Y injection on glucose metabolism in fasted rats. *Clinical Science*, **1995**, 89, 543-8	6.5	7
97	Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. *Diabetes Care*, **2021**, 44, 1159-1167	14.6	7
96	Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to IDegLira. *Diabetic Medicine*, **2016**, 33, 864-76	3.5	7
95	Consensus recommendations on exploring effective solutions for the rising cost of diabetes. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*, **2017**, 11, 141-147	8.9	6
94	Response by Kosiborod et al to Letters Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)". *Circulation*, **2018**, 137, 989-991	16.7	6
93	Beyond lifestyle interventions: exploring the potential of anti-obesity medications in the UK. *Clinical Obesity*, **2018**, 8, 211-225	3.6	6
92	SGLT2 inhibitors: providing cardiovascular protection in type 2 diabetes?. *Lancet Diabetes and Endocrinology,the*, **2016**, 4, 379-81	18.1	6
91	Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes. *Expert Opinion on Emerging Drugs*, **2013**, 18, 375-91	3.7	6
90	The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula performs worse than the Modification of Diet in Renal Disease (MDRD) equation in estimating glomerular filtration rate in Type 2 diabetic chronic kidney disease. *Diabetic Medicine*, **2011**, 28, 1279	3.5	6
89	Pathophysiology and aetiology of obesity. *Medicine*, **2011**, 39, 6-10	0.6	6
88	Growth hormone and changes in energy balance in growth hormone deficient adults. *European Journal of Clinical Investigation*, **2008**, 38, 622-7	4.6	6

87	Body weight and prolactinoma: a retrospective study. *International Journal of Obesity*, **2004**, 28, 183	5.5	6
86	SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes. *Diabetes Therapy*, **2020**, 11, 2757-2774	3.6	6
85	Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus. *Current Medical Research and Opinion*, **2020**, 36, 571-581	2.5	6
84	Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 Diabetes (SCORE-IT): study protocol for the development of a core outcome set. *Trials*, **2018**, 19, 427	2.8	6
83	Adipokines: emerging therapeutic targets. *Current Opinion in Investigational Drugs*, **2009**, 10, 1061-8		6
82	Dapagliflozin and cardiovascular outcomes in patients with Type 2 diabetes. *Future Cardiology*, **2020**, 16, 77-88	1.3	5
81	Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes. *Diabetic Medicine*, **2020**, 37, 1793-1806	3.5	5
80	Glycaemic, weight, and blood pressure changes associated with early versus later treatment intensification with dapagliflozin in United Kingdom primary care patients with type 2 diabetes mellitus. *Diabetes Research and Clinical Practice*, **2019**, 155, 107791	7.4	5
79	Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials. *Diabetes Therapy*, **2019**, 10, 2201-2217	3.6	5
78	In humans the adiponectin receptor R2 is expressed predominantly in adipose tissue and linked to the adipose tissue expression of MMIF-1. *Diabetes, Obesity and Metabolism*, **2010**, 12, 360-3	6.7	5
77	Obesity and risk of myocardial infarction: the INTERHEART study. *Lancet, The*, **2006**, 367, 1053	40	5
76	Metabolic actions of neuropeptide Y and their relevance to obesity. *Biochemical Society Transactions*, **1996**, 24, 576-81	5.1	5
75	Endocrine testing in obesity. *European Journal of Endocrinology*, **2020**, 182, C13-C15	6.5	5
74	Strengthening resistance to the COVID-19 pandemic and fostering future resilience requires concerted action on obesity. *Global Health Action*, **2020**, 13, 1804700	3	5
73	The clinical management of diabetes mellitus **2014**, 305-332		4
72	Ectopic lipid storage in non-alcoholic fatty liver disease is not mediated by impaired mitochondrial oxidative capacity in skeletal muscle. *Clinical Science*, **2014**, 127, 655-63	6.5	4
71	Anti-obesity Drugs: From Animal Models to Clinical Efficacy **2008**, 271-315		4
70	Response: Postprandial Adiponectin Revisited. *Obesity*, **2004**, 12, 1032-1034		4

69	Management of hypertension **2000**, 320, 576-576		4
68	Obstructive sleep apnoea in diabetes - assessment and awareness. *British Journal of Diabetes and Vascular Disease*, **2014**, 14, 105		4
67	The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. *Diabetologia*, **2021**, 64, 1226-1234	10.3	4
66	Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. *JAMA Cardiology*, **2021**, 6, 801-810	16.2	4
65	Screening methods for obstructive sleep apnoea in severely obese pregnant women. *Clinical Obesity*, **2017**, 7, 239-244	3.6	3
64	Modern management of obesity. *Clinical Medicine*, **2009**, 9, 617-21; quiz 622-3	1.9	3
63	Clinical Investigations of Antiobesity Drugs **2007**, 337-III		3
62	Metabolic syndrome is associated with reduced flow mediated dilation independent of obesity status. *European Journal of Endocrinology*, **2020**, 183, 211-220	6.5	3
61	Vitamin D3 analogues ZK159222 and Zk191784 have anti-inflammatory properties in human adipocytes **2016**, 1,		3
60	Changes in Energy Balance during Dapagliflozin Therapy in Type 2 Diabetes□he Energize Study. *Diabetes*, **2018**, 67, 1163-P	0.9	3
59	1101-P: Cardiorenal Outcomes with Dapagliflozin by Baseline Glucose Lowering Agents: Analyses from DECLARE-TIMI 58. *Diabetes*, **2020**, 69, 1101-P	0.9	3
58	The future of obesity treatment. *Exs*, **2000**, 89, 181-91		3
57	Dapagliflozin for the treatment of type 2 diabetes mellitus - an update. *Expert Opinion on Pharmacotherapy*, **2021**, 22, 2303-2310	4	3
56	1□25(OH)D attenuates IL-6 and IL-1□mediated inflammatory responses in macrophage conditioned medium-stimulated human white preadipocytes by modulating p44/42 MAPK and NF-□B signaling pathways. *Diabetology and Metabolic Syndrome*, **2019**, 11, 9	5.6	2
55	Cerebral activations during viewing of food stimuli in adult patients with acquired structural hypothalamic damage: a functional neuroimaging study. *International Journal of Obesity*, **2015**, 39, 1376-82	5.5	2
54	Why I eat at night: A qualitative exploration of the development, maintenance and consequences of Night Eating Syndrome. *Appetite*, **2018**, 125, 270-277	4.5	2
53	Weighing up dietary patterns - Authors□eply. *Lancet, The*, **2016**, 388, 759-60	40	2
52	Urinary proteomic profiling in severe obesity and obstructive sleep apnoea with CPAP treatment. *Sleep Science*, **2015**, 8, 58-67	1.8	2

51	Pharmacological Approaches for Treating Obesity421-446		2
50	Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance: does it really work? If yes, is it a novelty?. *Diabetic Medicine*, **2005**, 22, 666-7; author reply 667	3.5	2
49	Glucose metabolism and the pathophysiology of diabetes mellitus **2014**, 273-304		2
48	Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnoea-hypopnoea index (AHI). *BMJ Open*,	3	2
47	A andomisd, controlled, double blind tudy to assess mechanstic effects of combination therapy of dapagflozin with xenatide QW versus dapagliflozin alone i obese patients with ype 2 diabetes mellitus (RESILIENT): study protocol. *BMJ Open*, **2021**, 11, e045663	3	2
46	The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review.. *Diabetes Therapy*, **2022**, 13, 847	3.6	2
45	Semaglutide in weight management - Author's reply. *Lancet, The*, **2019**, 394, 1226-1227	40	1
44	Endocrine effects of gastrointestinal tumours. *Endocrine-Related Cancer*, **1997**, 4, 179-189	5.7	1
43	Weight management and cardiovascular disease: implications of recent and ongoing clinical trials. *British Journal of Diabetes and Vascular Disease*, **2008**, 8, 170-176		1
42	Pathophysiology and Aetiology of Obesity. *Medicine*, **2003**, 31, 1-4	0.6	1
41	Ghrelin: sweet regulation?. *Clinical Science*, **2002**, 103, 329-30	6.5	1
40	Obesity and Type 2 diabetes mellitus. *Diabetic Medicine*, **2000**, 17, 400-2	3.5	1
39	Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58.. *Diabetes Care*, **2022**, 45, e27-e29	14.6	1
38	Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial. *BMJ Open*, **2020**, 10, e034137	3	1
37	1020-P: Semaglutide-Induced Weight Loss Is Associated with Improved Health-Related Quality of Life and Treatment Satisfaction. *Diabetes*, **2019**, 68, 1020-P	0.9	1
36	Weight loss is the major player in bariatric surgery benefits. *Nature Medicine*, **2020**, 26, 1678-1679	50.5	1
35	Realising the full potential of data-enabled trials in the UK: a call for action. *BMJ Open*, **2021**, 11, e043906	3	1
34	Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors. *Drugs*, **2021**, 81, 1243-1255	15.1	1

33	The 1,25(OH)D Analogs ZK159222 and ZK191784 Show Anti-Inflammatory Properties in Macrophage-Induced Preadipocytes via Modulating the NF-B and MAPK Signaling. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, **2020**, 13, 1715-1724	3.4	0
32	Blood pressure control and ACE inhibitor/angiotensin receptor blocker usage. *Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide*, **2008**, 25, 54-58		0
31	Exercise in Obesity-the Role of Technology in Health Services: Can This Approach Work?. *Current Obesity Reports*, **2021**, 1	8.4	0
30	Short-Term Physical Inactivity Induces Endothelial Dysfunction. *Frontiers in Physiology*, **2021**, 12, 659834	4.6	0
29	Metabolically healthy obesity: time for a change of heart?. *Nature Reviews Endocrinology*, **2021**, 17, 519-520	12.2	0
28	A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. *Diabetes Care*, **2021**, 44, 2573-2581	14.6	0
27	PARIS: protocol for a prospective single arm, theory-based, group-based feasibility intervention study to increase Physical Activity and reduce sedentary behaviouR after barIatric Surgery.. *BMJ Open*, **2021**, 11, e051638	3	0
26	Etiopathogenesis of Obesity **2016**, 13-20		
25	Obesity and Obstructive Sleep Apnea Syndrome. *Endocrinology*, **2018**, 1-30	0.1	
24	Reply to Camargo et al. *Diabetic Medicine*, **2012**, 29, 1086-7; author reply 1087-8	3.5	
23	Obesity and cardiovascular risk in type 2 diabetes **2015**, 119-128		
22	232 DIFFERENTIAL GENETIC EXPRESSION AND REDUCED LONGITUDINAL FUNCTION IN PATIENTS WITH DIABETES AND SEVERE AORTIC STENSOIS WITH A NORMAL EJECTION FRACTION. *Heart*, **2013**, 99, A125.1-A125	5.1	
21	The endocrinologist and respiratory failure **2010**, 391-398		
20	Necrolytic migratory erythema: a classical cutaneous presentation of the glucagonoma syndrome. *Journal of the European Academy of Dermatology and Venereology*, **1997**, 9, 68-73	4.6	
19	An elderly type 1 diabetic patient with life event-related brittle diabetes. *Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide*, **2007**, 24, 130-131		
18	Applied physiology: The control of weight. *Current Paediatrics*, **2006**, 16, 439-446		
17	Peripheral injection of risperidone, an atypical antipsychotic, alters the body weight gains of rats. *Clinical and Experimental Pharmacology and Physiology*, **2003**, 30, 513-4; author reply 514-5	3	
16	Is Obesity Realistically Treatable in Type 2 Diabetes?73-87		

List of Publications

15	Evolution of Early Changes in Heart Rate Variability following Acute Myocardial Infarction. *Clinical Science*, **2000**, 99, 15P-16P	
14	Sympathovagal Balance in Growth Hormone Deficient Patients. *Clinical Science*, **1999**, 97, 6P-6P	
13	Regulation of energy balance Towards rational drug design in obesity **2008**, 21-46	
12	Intestinal lipase inhibitors **2008**, 47-57	
11	Sibutramine **2008**, 59-68	
10	The endocannabinoid system as a target for obesity treatment **2008**, 69-80	
9	HbA1c, Weight, and Blood Pressure Changes Associated with Early vs. Late Treatment Intensification with Dapagliflozin in U.K. Primary Care Patients with Type 2 Diabetes. *Diabetes*, **2018**, 67, 1186-P	0.9
8	Dapagliflozin plus Saxagliptin Add-On to Metformin Reduces Liver Fat and Adipose Tissue Volume in Patients with Type 2 Diabetes. *Diabetes*, **2018**, 67, 1175-P	0.9
7	Relatively Consistent Effects of Canagliflozin (CANA) on Outcomes Regardless of Baseline HbA1c in the CANagliflozin CardioVascular Assessment Study (CANVAS) Program. *Diabetes*, **2018**, 67, 1191-P	0.9
6	Design of a randomised controlled trial: does indirect calorimetry energy information influence weight loss in obesity?. *BMJ Open*, **2021**, 11, e044519	3
5	Research update for articles published in EJCI in 2014. *European Journal of Clinical Investigation*, **2016**, 46, 880-94	4.6
4	Obesity and Obstructive Sleep Apnea Syndrome. *Endocrinology*, **2019**, 243-271	0.1
3	Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy. *Diabetes, Obesity and Metabolism*, **2022**, 24, 61-71	6.7
2	Etiopathogenesis of Obesity **2021**, 1-12	
1	Adjunctive Therapy, Including Pharmacotherapy **2022**, 279-296	